Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK, and what generic alternatives to MERCK drugs are available?
MERCK has ninety-two approved drugs.
There are twenty-six US patents protecting MERCK drugs.
There are seven hundred and thirty-five patent family members on MERCK drugs in sixty-three countries and one hundred and seventy-eight supplementary protection certificates in nineteen countries.
Summary for Merck
International Patents: | 735 |
US Patents: | 26 |
Tradenames: | 77 |
Ingredients: | 70 |
NDAs: | 92 |
Patent Litigation for Merck: | See patent lawsuits for Merck |
PTAB Cases with Merck as patent owner: | See PTAB cases with Merck as patent owner |
Drugs and US Patents for Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Kgaa | LEVOTHYROXINE SODIUM | levothyroxine sodium | TABLET;ORAL | 076752-011 | Jun 16, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | 8,513,255 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Merck | PRINZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019778-003 | Nov 18, 1993 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | JUVISYNC | simvastatin; sitagliptin phosphate | TABLET;ORAL | 202343-004 | Sep 18, 2012 | 6,303,661 | ⤷ Try a Trial |
Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-001 | Dec 29, 1987 | 4,374,829*PED | ⤷ Try a Trial |
Merck And Co Inc | EMEND | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 022023-001 | Jan 25, 2008 | 7,214,692 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
➤ Subscribe | Oral Solution | 70 mg/75 mL | ➤ Subscribe | 2007-09-07 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | For Injection | 50 mg/vial and 70 mg/vial | ➤ Subscribe | 2009-06-26 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
International Patents for Merck Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 1819700 | ⤷ Try a Trial |
Cyprus | 1117372 | ⤷ Try a Trial |
Lithuania | C2576547 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1622880 | C01622880/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: AICURIS ANTI-INFECTIVE CURES GMBH, DE |
2576547 | 30/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 (MITTEILUNG) 20210720 |
0720599 | 122004000026 | Germany | ⤷ Try a Trial | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 58866.00.00 58866.01.00 58866.02.00 58866.03.00 58870.00.00 58870.01.00 58870.02.00 58870.03.00 58874.00.00 58874.01.00 58874.02.00 58874.03.00 58878.00.00 58878.01.00 58878.02.00 58878.03.00 20040402 FIRST REGISTRATION: DE 58866.00.00 - 58866.03.00 58870.00.00 - 58870.03.00 58874.00.00 - 58874.03.00 58878.00.00 - 58878.03.00 20040402 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.